Background: The increased use of the androgen receptor axis-targeted (ARAT) agents abiraterone and enzalutamide in first-and second-line treatment of metastatic castration-resistant prostate cancer (mCRPC) has improved patient outcomes, but resistance to these agents is inevitable. Early identification of patients with primary or secondary resistance to ARAT therapy is of increasing clinical concern.
introduction
Prostate cancer (PC) is a major global health concern, as the most common malignancy among men in economically developed countries and second to lung cancer worldwide [1] . In 2012, an estimated 1.1 million (15% of all cancers diagnosed in men) new PC cases were diagnosed worldwide, and 307 000 (6.6%) men died of the disease, making it the fifth leading cause of death from cancer in men [2] .
The androgen receptor (AR) is a nuclear hormone receptor predominately dependent on activation by dihydrotestosterone, a ligand produced through intracellular conversion of testosterone, to induce nuclear localization and target gene transcription [3] . The AR is commonly involved in driving PC development and progression, and many agents used to treat PC target the AR signaling axis. Androgen deprivation therapy (ADT) by medical or surgical means [4] [5] [6] [7] [8] has been used as the main component of first-line PC therapy in the metastatic state. Although disease regression and stability may occur for varying lengths of time, disease progression is inevitable and reactivation of ARaxis signaling has been identified as an important driver of this process [9] . The loss of response to ADT, leading to castration-resistant prostate cancer (CRPC), is associated with compensatory mechanisms allowing post-castration activation of the AR, including AR gene amplification, mutation, incomplete blockade of ligand-dependent AR activation, and aberrant AR co-regulator activity, among other mechanisms [10] [11] [12] [13] [14] .
With the recent development and widespread adoption of the androgen biosynthesis inhibitor abiraterone acetate (hereafter referred to as abiraterone) [15] [16] [17] and the novel antiandrogen enzalutamide [18, 19] for the treatment of metastatic castrationresistant prostate cancer (mCRPC), these agents have become the most commonly used AR-axis-targeted (ARAT) therapies in this setting. Both abiraterone and enzlutamide have been associated with improvements across a spectrum of clinical outcomes and high response rates of prolonged duration, particularly for chemotherapy-naïve patients. Other non-ARAT agents approved for treatment of mCRPC in recent years include cabazitaxel [20] , a second-generation taxane designed to overcome docetaxel resistance, the immunotherapeutic agent sipuleucel-T [21] and the bone-targeting radiotherapy Radium-223 [22] .
Despite these mCRPC treatment advances, primary resistance to ARAT therapy and the development of secondary resistance remain clinical challenges. In the pivotal trials with abiraterone and enzalutamide, primary resistance was observed in both chemotherapy experienced and naïve mCRPC patients [15] [16] [17] [18] [19] . In patients previously treated with chemotherapy, the proportion of patients showing radiographic progression and prostate-specific antigen (PSA) progression within the first 3 months of treatment was ∼35% and 15%, respectively, for abiraterone [15] and 25% and 10%, respectively, for enzalutamide [18] . In chemotherapynaïve populations, radiographic progression and PSA progression within the first 3 months was ∼5% and 8%, respectively, for abiraterone [17] and 5% and 3%, respectively, for enzalutamide [19] .
Proposed mechanisms of resistance to abiraterone and enzalutamide include alternate signaling pathways to induce steroid synthesis, AR gene amplification, increased expression of ligandindependent AR splice variants [23, 24] , and mutations that confer resistance to AR antagonists and promiscuous activation by alternative ligands, including AR antagonists, glucocorticoids, or progesterone ( Figure 1 ) [24] [25] [26] [27] [28] . Despite distinct mechanisms of action, abiraterone and enzalutamide both target AR-axis signaling [15] [16] [17] [18] [19] and share mechanisms associated with treatment resistance [23, 24] ; therefore, there is potential for cross resistance.
There is level 1 evidence supporting the establishment of ARAT agents and other therapies as first-or second-line treatment for mCRPC, yet robust clinical data to guide the optimal sequencing of these therapies are lacking. The best available evidence to inform patient selection, duration of treatment, and survival is retrospective. Our review focuses on treatment options for mCRPC; therefore, ARAT therapy will hereafter be used to specifically indicate abiraterone and enzalutamide. We provide a systematic review and interpretation of available clinical data addressing the diagnosis and treatment of ARAT therapy-resistant mCRPC. ; 2013-2014) , and the European Cancer Congress (ECC; 2013) were searched for studies of agents used after progression on ARAT therapies (specifically abiraterone and enzalutamide). The key search terms (or aliases) mCRPC, abiraterone, and enzalutamide were used, and results were limited to clinical trials and comparative or validation studies ( Figure 2) . A supplemental bibliographic search of recent review articles and directed searches of ASCO GU 2015 for updated reports of specific studies was also conducted. A total of 447 records were identified from selected sources.
findings
A total of 70 prognostic/predictive studies were identified (24 assessing biomarkers; 46 assessing clinical/biological factors; Figure 2 ). Relevant treatment outcomes were identified from a total of 44, predominately retrospective, studies ( Figure 2) , with some assessing multiple treatment cohorts (total cohorts n = 60). For pragmatic reasons, outcomes for cohorts assessing fewer than 15 patients (n = 14) were excluded from the analysis due to their highly variable nature, resulting in a final data set of 46 treatment cohorts. Predictive markers of treatment response are key tools for identifying patients who are likely to be resistant to therapy. One should note that the possible usefulness of these markers is largely agent-specific and may not be generalized to other therapies until validated. Laboratory biomarkers of interest in predicting response or resistance to ARAT therapy for mCRPC have focused on aberrations in AR gene or protein expression [28] [29] [30] [31] [32] [33] [34] [35] [36] . AR amplification occurs in 50% or more CRPC patients [37] , and has been associated with both response and resistance to ARAT therapy. Increased AR copy number following initial ADT has been associated with improved response to subsequent combined androgen blockade [36] , while more recent data have shown that AR copy number gain in circulating tumor DNA (ctDNA) is associated with poor response to the ARAT agents abiraterone and enzalutamide [33, 38] . AR mutations, particularly in the ligand-binding domain, that confer resistance to AR antagonists or activation by glucocorticoids or progesterone have also been explored for association with response to ARAT therapy, with some studies indicating an association with disease progression and treatment resistance [25, 27, 28, 33, 38] .
Other potential biomarkers include nuclear AR [29, 39] and cytoplasmic CYP17 expression [29] . High nuclear AR expression combined with ≥10% cytoplasmic CYP17 expression in bone metastases has been significantly correlated with improved outcomes following treatment with abiraterone plus prednisone [29] , and following enzalutamide therapy [30] . However, further studies are necessary to validate the correlation between these biological factors and resistance to therapy.
Recently, compelling data have emerged on the expression of the AR splice variant AR-V7, which lacks the ligand-binding domain of the receptor [31, 40] . Patients initiating treatment with either abiraterone (n = 31) or enzalutamide (n = 31) were prospectively enrolled in a single-center study to assess association between AR-V7 status and treatment outcomes [31] . Analysis of AR-V7 expression in circulating tumor cell (CTC) RNA showed that men receiving abiraterone who were positive for AR-V7 expression had lower rates of PSA response, defined as a ≥50% PSA decline (0 versus 68%, P = 0.004), as well as shorter median PSA progression-free survival (PFS; 1.3 months versus not reached; P < 0.001), median clinical or radiographic PFS (2.3 months versus not reached; P < 0.001), and median overall survival (OS; 10.6 months versus not reached, P = 0.006) than those who were AR-V7 negative. Likewise, men receiving enzalutamide who were positive for AR-V7 expression showed lower rates of PSA response (0 versus 53%, P = 0.004), and shorter median PSA-PFS (1.4 versus 6.0 months; P < 0.001), median clinical or radiographic PFS (2.1 versus 6.1 months; P < 0.001), and median OS (median, 5.5 months versus not reached; P = 0.002) [31] . A similar, albeit smaller, prospective study (n = 37) was conducted to assess taxane activity in these patients [41] . Although small numerical differences in favor of AR-V7-negative status were apparent, differences were not statistically significant for PSA response (41 versus 65%, P = 0.19), PSA-PFS (4.5 versus 6.2 months, HR 1.72, P = 0.32) or median PFS (5.1 versus 6.9 months, HR 2.65, P = 0.11) in AR-V7-positive compared with AR-V7-negative patients.
Although the results of these AR-V7 biomarker studies are promising, findings must be interpreted with caution given that they were derived from small, single-center trials conducted in heterogeneous and heavily pretreated patient populations where treatment was not selected in a randomized fashion. Additionally, the possibility remains that AR-V7 is generally prognostic rather than predictive of response to ARAT therapy, given the likelihood that the taxane AR-V7 study was insufficiently powered to detect differences in treatment outcomes. It is therefore unclear how these findings apply in less heavily treated populations and in settings where processes for detection and analysis of CTCs are not standardized. Large-scale, prospective validation of potential biomarkers is necessary before these cellular and molecular signatures can be used to guide treatment strategy. Prospective evaluation of several laboratory biomarkers are underway, where correlative studies are integrated into multi-center clinical trials randomizing patients to treatment with ARAT agents or chemotherapy (clinicaltrials.gov: NCT02125357 and NCT02254785). These types of trials will provide robust data that are critical to validate candidate biomarkers and assess clinical utility.
prognostic and predictive clinical factors and models
Given the substantial heterogeneity of disease outcomes and absence of validated laboratory biomarkers, identifying patients with particularly poor prognosis and those potentially resistant to ARAT therapy can help determine which patients are susceptible to treatment failure, and allow consideration of alternative treatment options as early as possible. A total of 46, primarily retrospective, studies investigating either individual factors or prognostic models were identified ( Figure 2 ).
These factors include the duration of response to prior ADT, PSA response, Gleason score, baseline serum androgen levels, and chromogranin A levels (summarized in Table 1 ); however, none has been validated as predictive of response to ARAT treatment.
Among the individual prognostic factors investigated for association with outcomes to ARAT therapy, the duration of response to prior ADT has been of interest based on the assumption that patients with poor response or rapid progression on first-line ADT are unlikely to respond to further AR-directed therapies (Table 1) . Two retrospective analyses of institutional cohorts have indicated a relationship between the degree of response to prior ADT and response to AR-targeted therapy (including ARAT agents and other hormonal therapies, e.g. antiandrogen, diethystilboestrone, estramustine, ketoconazole) in chemotherapy-exposed populations [42, 43] . These studies suggest that shorter durations of previous sensitivity to ADT (<16 versus ≥16 months) [42] and shorter responses to surgical or chemical castration therapy (<12versus ≥12 months) [43] indicate a poor likelihood of response to ARAT agents. Data on treatment with taxanes demonstrate a reduced time to biochemical progression [43] , reduced time to progression and shorter OS among patients with <1 year response to ADT, although similar rates of PSA response [43, 57] and clinical benefit [57] were observed regardless of the duration of response to prior ADT or time to CRPC. Finally, retrospective analysis of data from the TROPIC trial show that OS was shorter in cabazitaxeltreated patients with a shorter duration of prior hormonal therapy [58] . The relationship between shorter response to prior hormonal therapy and poor likelihood of response to ARAT agents may indicate resistance across therapies targeting the AR axis, a plausible hypothesis considering their shared mechanisms of treatment resistance. However, given a similar trend of reduced benefit of taxanes with shorter duration of prior hormonal therapy, it is unclear whether the duration of prior ADT should be considered in treatment decisions. Even so, pending more robust clinical data, a recently published European Consensus, have indicated that a short duration of response (<1 year) to first-line ADT may be useful in identifying patients with an increased risk of primary resistance to AR-axis-targeted agents [59] .
Given the limitations of individual prognostic factors, research is underway to develop and validate prognostic models based on multiple clinical factors. A study of the COU-AA-301 database of mCRPC patients pretreated with docetaxel-assessed clinical factors [lactate dehydrogenase (LDH) level, Eastern Cooperative Oncology Group performance status, presence or absence of liver metastases, serum albumin and alkaline phosphatase (ALP) levels] and time from the start of ADT to initiation of therapy at baseline to identify independent prognostic factors for OS (Table 1 ) [54] . Patients were assigned to risk groups based on the number of baseline factors, good (0 or 1), intermediate (2 or 3) , and poor (4-6). Patients in the poor risk group who were treated with abiraterone had a lower median OS compared with those in the good risk group (6.1 versus 21.3 months) [54] . The differences in median OS in poor prognosis patients treated with abiraterone compared with placebo appeared to be modest, emphasizing that poor prognosis cannot be interpreted as predictive of poor response to abiraterone. This prognostic model has been validated in both population-based and independent retrospective cohort analyses [60, 61] .
Both neutrophil-lymphocyte ratio (NLR) and extent of metastatic disease have also been studied as a factors associated with poor response to ARAT therapy and assessed in prognostic models. A recent study by Leibowitz-Amit et al. [55] sought to identify factors associated with PSA response to abiraterone, and validate this association in an independent cohort ( Table 1) . The group identified an institutional cohort of 108 abirateronepretreated mCRPC patients. A univariate analysis of potential factors to predict response to abiraterone therapy demonstrated that a score derived from the sum of NLR ≤ 5 and restricted metastatic spread was significantly associated with PSA response to abiraterone therapy (P = 0.007). Validation with an independent cohort of 245 mCRPC patients verified the predictive capacity of the score and demonstrated an association with OS. Patients with a score of 2 (NLR > 5 and extensive metastatic spread, defined as visceral involvement or combined bone and lymph node disease) had a poor response to abiraterone therapy (P = 0.003). A recently developed prognostic model, incorporating NLR, was evaluated in a cohort of chemotherapy-naïve mCRPC patients (n = 357) treated with docetaxel (Table 1 ) [56] . Multi-variable analysis indicated that liver metastases, low hemoglobin, high ALP, LDH, and NLR were associated with decreased survival. In conclusion, considerable research has been conducted to elucidate the underlying mechanisms of clinical resistance to ARAT therapy in the hope of identifying new treatment approaches and potential predictive factors. Potential biomarkers, such as AR-V7 splice variant expression and other AR gene aberrations (e.g., mutation, copy number increase) [31, 33, 38] and clinical and laboratory factors, such as short duration of response to initial ADT, early response, features of poor prognosis, androgen levels by ultrasensitive assays, and NLR (Table 1) , hold promise for considerable clinical utility [42-45, 48-51, 54-56, 60, 61] . Presently, however, caution must be used when applying these hypothesis-generating findings clinically, highlighting the need for further validation. Although treatment with greater lines of therapy (3 versus 2) has been associated with improved OS [62] , the optimal sequencing of agents following docetaxel and ARAT therapy is not well-defined.
third-line outcomes for ARAT therapy or chemotherapy following progression on docetaxel and ARAT therapy. Outcomes for ARAT therapy or cabazitaxel as third-line treatments are available from multiple retrospective analyses and early access Androgen biosynthesis inhibitors (ABS): abiraterone, 75%; oteronel, 35%; ketoconazole, 5%; more than one, 15%. q Time from start of abiraterone to time of PSA progression (PSA increase of 25% from nadir and a minimum of 2 ng/ml), radiographic progression, and/or symptomatic progression. r n = 74 evaluated for PSA response, determined from max PSA change in waterfall plot. s Estimated from graph, no numerical data available. t 1 patient (1.4%) received enzalutamide or placebo before abiraterone-cabazitaxel; 5 patients (7.2%) received enzalutamide or placebo between abiraterone and cabazitaxel. Table 2 ). A total of 16 retrospective cohort analyses assessed the effectiveness of a second ARAT therapy after progression on prior docetaxel and ARAT treatment (Table 2) [63] [64] [65] [66] [67] [68] [69] [70] [71] [72] [73] [74] [75] [76] [77] [78] . Enzalutamide was the most investigated agent in this setting (docetaxel followed by abiraterone, followed by enzalutamide, D-A-E; n = 14 cohorts) [63] [64] [65] [66] [67] [68] [69] [70] [71] [72] [73] [74] [75] [76] . Rates of ≥50% PSA decline data were available for the majority of D-A-E cohorts (n = 13) and were highly variable, ranging from 12% to 40%. Median PFS for third-line enzalutamide ranged from 2.8 to 4.9 months (n = 7 cohorts) [63, 65, 66, [68] [69] [70] 72] , while median OS outcomes ranged from 4.8 to 10.6 months (n = 6 cohorts) [63, 66, 68, 71, 73, 74] . Abiraterone outcomes in this setting were examined in only two studies (docetaxel followed by enzalutamide, followed by abiraterone, D-E-A) [77, 78] , with rates of ≥50% PSA decline of 4% and 8%, respectively. Survival outcomes for third-line abiraterone were reported for both studies, with median PFS of 2.7 months and 3.5 months and median OS of 7.2 months and 11.5 months, respectively.
Cabazitaxel outcomes have been investigated in a total of 10 retrospective analyses in docetaxel and ARAT therapypretreated patients (docetaxel-abiraterone-cabazitaxel or docetaxel-enzalutamide-cabazitaxel [D-A/E-C] sequences; Table 2 ) [32, 69, [79] [80] [81] [82] [83] [84] [85] . Findings from these cohort analyses also show substantial variability, with ≥50% PSA decline data ranging from 25% to 46% (n = 8 cohorts; Table 2 ). Median PFS outcomes for third-line cabazitaxel were reported for eight D-A/E-C cohorts, and ranged from 4 to 5.9 months [32, 69, 79-81, 84, 85] , while median OS was reported for four cohort analyses, with values ranging from 8.2 to 15.8 months [79, 80, 83, 85] . Data on the use of docetaxel rather than cabazitaxel is limited, and outcomes from a single study examining retreatment with docetaxel (docetaxel followed by abiraterone, then docetaxel, D-A-D; n = 49) suggest activity in this context (≥50% PSA decline of 37%) [86] .
second-line treatment outcomes in chemotherapy-naïve patients previously treated with abiraterone. Since the publication of results from COU-AA-302 and PREVAIL showing improved outcomes in patients receiving abiraterone or enzalutamide prior to docetaxel therapy [17, 19] , an increasing number of patients who progress on first-line ARAT treatment are chemotherapynaïve. Although abiraterone, enzalutamide, and cabazitaxel have all demonstrated activity as second-line treatment for mCRPC in docetaxel-pretreated patient populations [15, 18, 87] , their role in chemotherapy-naïve, ARAT therapy-pretreated populations is less clear. It is therefore important to consider trials that address the optimal sequencing of these agents as second-line treatment in chemotherapy-naïve patients.
Overall, 12 cohort analyses assessed the effectiveness of a second ARAT therapy or docetaxel in ARAT therapy-pretreated, chemotherapy-naïve populations [64, 66, 86, [88] [89] [90] [91] [92] [93] [94] . Enzalutamide outcomes, after prior abiraterone (A-E), were assessed in a total of four retrospective studies in this setting [64, 66, 88, 89] . Rates of ≥50% PSA decline data available from three studies ranged from 25.5% to 36% [64, 66, 89] , and median OS of 8.6 months was reported in one study (n = 47; Table 3 ) [66] . Abiraterone outcomes were assessed in a post-hoc analysis of data from the COU-AA-302 trial; positive PSA response was reported (Table 3 , see footnote) [88] . [86] Retro MC Cohort 37 -32 -Zafeiriou et al. [90] Retro SC Cohort 37
Retro SC Cohort 35 5 26 12.5 Suzman et al. [89] Retro SC Cohort 31 -40 -Schweizer et al. [92] Retro SC Cohort 24 -38 -Aggarwal et al. [93] Retro SC Cohort Cohort of patients who received abiraterone following discontinuation of initial abiraterone in COU-AA-302 study; patients were chemotherapy -naïve prior to initial treatment with abiraterone, and 69% (n = 38) received intervening chemotherapy prior to subsequent abiraterone. Table 3 ) [86, [89] [90] [91] [92] [93] [94] . Results from six of these studies included rates of ≥50% PSA decline ranging from 26% to 48% [86, 89, [91] [92] [93] [94] , and median OS outcomes for two studies were reported as 12.5 and 12.4 months, respectively [91, 93] .
Studies of the use of alternate treatment options in the secondline, chemotherapy-naïve setting, such as the androgen biosynthesis inhibitor ketoconazole, the HSP90 inhibitor AT13387, and the next-generation AR inhibitor ODM-201, have also been undertaken, although limited data are available [51, [95] [96] [97] [98] .
Retrospective analyses of mCRPC treatment data have described outcomes for a variety of second-and third-line treatments in both the chemotherapy-experienced and naïve settings (Tables 2 and 3) . However, such analyses are prone to multiple biases and cross trial comparisons are discouraged. Despite this, there are some consistent trends that may help guide therapy in the absence of randomized data. There is a trend toward reduced response to ARAT treatment after prior ARAT therapy, which may reflect a degree of cross-resistance [70, 71, 77, 78] arising from common mechanisms of resistance, such as increased expression of splice variants or AR amplification [31, 33, 38, 99] . Despite controversial pre-clinical and early clinical evidence suggesting cross-resistance between ARAT therapy and taxane chemotherapy [80, 85, 86, 91, [100] [101] [102] [103] [104] , most clinical data suggest continued activity of both second-line docetaxel and third-line cabazitaxel in ARAT therapy-pretreated patients (Tables 2 and 3) , confirming the importance and relevance of chemotherapy in ARAT treatment-resistant patient populations.
discussion treatment sequencing
There are multiple treatment options available for ARAT therapy-resistant mCRPC [15, [17] [18] [19] 87] . When developing an individualized therapeutic strategy, patient factors such as age, co-morbid illnesses, functional status, agent tolerability, and clinical factors associated with poor response to ARAT therapy (Table 1 ), in conjunction with patient preferences, should be considered to guide treatment selection and sequencing. Between 3% and 25% of mCRPC patients may exhibit primary resistance to ARAT therapy [15, [17] [18] [19] to treatment is important for early identification. Lack of PSA decline or PSA progression within 3 months of start of treatment suggests primary resistance to an ARAT therapy [59] , indicating the need for a timely switch to an alternate ARAT therapy, or to chemotherapy while a patient's performance status remains favorable. Although primary or acquired resistance to either abiraterone or enzalutamide does not preclude a response to the other, resistance across agents is a possibility and close monitoring of treatment response is an important consideration when sequencing ARAT therapy [59] . Based on currently available prospective and retrospective data and our clinical experience, we suggest the following treatment algorithm to guide the treatment of patients with ARAT therapy-resistant mCRPC disease (Figure 3) . Although not specifically detailed throughout the algorithm, enrollment in a clinical a trial is recommended whenever feasible, and radium-223 is considered an appropriate option for patients with symptomatic bone metastases and no significant soft tissue disease at all levels, including those who are chemotherapy-ineligible. For first-line mCRPC patients progressing on ADT for PC, treatment with ARAT therapy is preferred for the majority of patients. However, docetaxel can be considered for patients with good performance status who are able to tolerate chemotherapy, suspected of ARAT treatment resistance (e.g., prior response to ADT < 1 year), symptomatic or have visceral metastatic disease.
For those receiving ARAT therapy in first-line, retrospective data suggest better responses to second-line docetaxel (Table 3) , although an ARAT therapy switch (i.e., enzalutamide following first-line abiraterone) may also be considered for patients with good response to prior ARAT therapy, >1 year response to prior ADT, asymptomatic or minimally symptomatic disease or have no visceral disease. In third-line, docetaxel is suggested for those who remain chemotherapy-naïve, while cabazitaxel is recommended for those pretreated with docetaxel.
Among patients receiving first-line docetaxel, second-line ARAT therapy is preferred (Figure 3) . However, treatment with cabazitaxel can be considered in patients with symptomatic disease, a poor response to prior ADT (<1 year), a prior prolonged response to docetaxel, or visceral disease. For third-line therapy following ARAT treatment, cabazitaxel is preferred based on retrospective evidence that suggests a trend toward greater response to cabazitaxel compared with ARAT therapy (Table 2) . However, an ARAT agent switch can be considered for asymptomatic or minimally symptomatic patients with a good response to prior ARAT therapy, good response to prior ADT (>1 year), and no visceral disease. For all patients progressing on third-line therapy and eligible for continued treatment, the therapeutic agent not yet given remains an option.
treatment challenges: AR-negative/neuroendocrine prostate cancer Effective inhibitors of AR-axis signaling may drive adaptive cellular responses and lead to an anaplastic, small cell or neuroendocrine phenotype characteristic of particularly aggressive and treatment-resistant mCRPC [105] [106] [107] . An increased proportion of neuroendocrine cells is found in high-grade and late-stage prostate tumors and is particularly common in CRPC. Neuroendocrine prostate cancer (NEPC) demonstrates a reduction or loss of ARsignaling, as indicated by the loss of AR expression and target gene transactivation (e.g., loss of PSA expression), as well as neuroendocrine cell-specific histological markers (e.g., CgA, synaptophysin, neuron-specific enolase) [108] .
The association of NEPC with high-risk and poor prognosis, combined with lack of AR expression, indicates high likelihood of resistance to ARAT therapy and more probable response to chemotherapy. The optimal treatment strategy for patients with NEPC must take into account individual patient and tumor characteristics, including the potential for mixed adenocarcinoma/neuroendocrine tumors that may retain AR expression and therefore have the potential for response to hormonal or ARAT therapy [109] ; however, patients with this PC variant commonly present with symptomatic disease and visceral (e.g., the liver, lung) metastases [105, 110] . For these high-risk patients with aggressive disease, first-and second-line platinum-based chemotherapy combinations have demonstrated robust initial, but not durable, responses with ultimately poor OS [111] . Much research to identify molecular targets and develop targeted agents for treatment of NEPC is underway [e.g., a phase II trial of the aurora kinase A inhibitor MLN8237 (NCT01799278)].
conclusion
The introduction of second-generation ARAT agents for treatment of first-and second-line mCRPC has improved outcomes, and the therapeutic landscape for PC continues to evolve as the benefits of these therapies are evaluated for earlier stages of disease. However, in mCRPC, resistance to ARAT agents is inevitable and identification of a clinically validated predictive biomarker remains elusive. Available retrospective data suggest that taxanes are a preferred treatment choice following ARAT therapy, although a switch to an alternate ARAT agent can be considered in select patients. Continued prospective research into predictive factors and optimal treatment sequencing for ARAT therapy-resistant mCRPC is warranted.
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